Brief: Fennec Pharmaceuticals Announces Settlement Agreement Resolving Pedmark Patent Litigation
March 16 (Reuters) - Fennec Pharmaceuticals Inc FENC.O: FENNEC PHARMACEUTICALS ANNOUNCES SETTLEMENT AGREEMENT RESOLVING PEDMARK PATENT LITIGATION FENNEC PHARMACEUTICALS INC - CIPLA BARRED FROM MARKETING GENERIC SODIUM THIOSULFATE UNTIL SEPTEMBER 1, 2033 FENNEC PHARMACEUTICALS INC: UNDER TERMS OF SETTLEMENT, LAWSUIT WILL BE DISMISSED WITH EACH PARTY BEARING THEIR OWN COSTS Source text: ID:nGNX9TGBKl Further company coverage: FENC.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cipla
See all newsFactbox: Global healthcare companies invest billions to boost US presence
Brief: Cipla, Qilu Pharmaceutical Partner For Licensing, Supply Of Biosimilar To Keytruda In US
India's Cipla, China's Qilu partner for US launch of Merck's Keytruda biosimilar
Brief: Cipla Enters Exclusive Partnership With Qilu For Keytruda Biosimilar In US
Brief: Cipla and SBP Group Sign Exclusive Licensing Agreement For HER2 Bispecific Antibody-Drug Conjugate